Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.54 |
| ▸ | MARS1 | P56192 | 7/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.41 |
| ▸ | BCL2 | P10415 | 4/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | RPA1 | P27694 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21887741 | 0.84 | NR1H2 (0.47) | NR1H2SMPD1MALT1 | |
| SCHEMBL16553554 | 0.82 | NR1H2 (0.77) | NR1H2MARS1MDM2MCL1BCL2 | |
| SCHEMBL20575099 | 0.78 | NR1H2 (0.37) | NR1H2 | |
| SCHEMBL17943738 | 0.77 | NR1H2 (0.71) | NR1H2MARS1MDM2MCL1BCL2 | |
| SCHEMBL17943746 | 0.77 | NR1H2 (0.58) | NR1H2MARS1MDM2MCL1BCL2 | |
| SCHEMBL16553537 | 0.73 | NR1H2 (0.79) | NR1H2MARS1MDM2MCL1 | |
| SCHEMBL16553481 | 0.72 | NR1H2 (0.58) | NR1H2MARS1MDM2MCL1BCL2 | |
| SCHEMBL16566131 | 0.71 | NR1H2 (0.73) | NR1H2MARS1 | |
| SCHEMBL25880809 | 0.71 | NR1H2 (0.41) | NR1H2 | |
| SCHEMBL16566090 | 0.70 | NR1H2 (1.00) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246419-B2 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246419-B2 | Liver X receptor (LXR) modulators | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.